Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dollar General Corp. (DG) vs GeneDx Holdings Corp (WGS) Price & Performance

Dollar General Corp.Trade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Dollar General Corp. vs GeneDx Holdings Corp — how do they compare? Dollar General Corp. trades at $119.42 (market cap $26.49B), while GeneDx Holdings Corp trades at $82.66 (market cap $2.44B). The key difference: Dollar General Corp. is far larger — about 10.9× GeneDx Holdings Corp's market cap, and Dollar General Corp. pays a 1.97% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

DGWGS
Market Cap
$26.49B$2.44B
Sector
Consumer StaplesTechnology
52-Week High
$156.26$167.51
52-Week Low
$95.94$34.51
Enterprise Value
$40.93B$2.48B
Dividend Yield
1.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dollar General Corp.

Dollar General (DG) trades at $122.39, down 3.32% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.00 surpassing the $1.89 expectation. Positive cash flow trends and a declining debt-to-asset ratio (20.03 in 2025) support financial health. A dividend of $0.59 is scheduled for payment on July 21, 2026.

The outlook is cautiously optimistic, with a consensus price target of $128.45 offering ~5% upside. Analyst sentiment is bullish (52% Buy ratings), but risks include competitive pressure from Walmart and Amazon, margin compression from rising costs, and market saturation. Revenue growth is projected to reach $43.1B in 2026, though net margin remains thin at 3.63%.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.

Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.

Returns comparison

Trailing returns across standard periods

About Dollar General Corp.

A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

Read more on DG

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS